Reports Q3 revenue $3.5M, consensus $4.25M. "I am proud of the SQZ team’s accomplishments this quarter, including our publication showcasing the AAC platform, advancing our autoimmune preclinical work, and progress made developing our integrated point-of-care manufacturing system," said Armon Sharei, Ph.D., CEO and Founder at SQZ Biotechnologies. "As we head into the final stretches of the year, we look forward to sharing the latest available clinical data from our three oncology trials."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SQZ:
- SQZ Biotechnologies initiated with a Buy at H.C. Wainwright
- SQZ Biotechnologies price target lowered to $15 from $40 at BTIG
- SQZ Biotechnologies publishes preclinical research on SQZ AAC platform
- SQZ Biotechnologies management to meet with BTIG
- SQZ Biotechnologies presents preclinical SQZ TIL data at ESMO